Literature DB >> 27790713

Emerging roles of RAC1 in treating lung cancer patients.

T Zou1,2, X Mao1,2, J Yin1,2, X Li1,2, J Chen1,2, T Zhu1,2, Q Li1,2, H Zhou1,2, Z Liu1,2.   

Abstract

The Ras-related C3 botulinum toxin substrate 1 (RAC1), a member of the Rho family of small guanosine triphosphatases, is critical for many cellular activities, such as phagocytosis, adhesion, migration, motility, cell proliferation, and axonal growth. In addition, RAC1 plays an important role in cancer angiogenesis, invasion, and migration, and it has been reported to be related to most cancers, such as breast cancer, gastric cancer, testicular germ cell cancer, and lung cancer. Recently, the therapeutic target of RAC1 in cancer has been investigated. In addition, some investigations have shown that inhibition of RAC1 can reverse drug-resistance in non-small cell lung cancer. In this review, we summarize the recent advances in understanding the role of RAC1 in lung cancer and the underlying mechanisms and discuss its value in clinical therapy.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RAC1; cell proliferation and apoptosis; invasion; lung cancer; migration

Mesh:

Substances:

Year:  2016        PMID: 27790713     DOI: 10.1111/cge.12908

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  18 in total

1.  Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation.

Authors:  Y Li; M Zhao; C Guo; H Chu; W Li; X Chen; X Wang; Y Li; Y Jia; S Koussatidjoa; F Zhu; J Wang; X Wang; Q Wang; W Zhao; Y Shi; W Chen; L Zhang
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

Review 2.  RACking up ceramide-induced islet β-cell dysfunction.

Authors:  Anjaneyulu Kowluru; Renu A Kowluru
Journal:  Biochem Pharmacol       Date:  2018-04-30       Impact factor: 5.858

Review 3.  Insulin and cancer: a tangled web.

Authors:  Brooks P Leitner; Stephan Siebel; Ngozi D Akingbesote; Xinyi Zhang; Rachel J Perry
Journal:  Biochem J       Date:  2022-03-18       Impact factor: 3.766

4.  STAT1, IGF1, RAC1, and MDM2 Are Associated with Recurrence of Giant Cell Tumor of Bone.

Authors:  Shuxin Chen; Zepeng Du; Bingli Wu; Huiyang Shen; Chunpeng Liu; Xueli Qiu; Yufeng Zhang; Liyan Xu; Enmin Li; Zhigang Zhong
Journal:  J Immunol Res       Date:  2018-01-31       Impact factor: 4.818

5.  The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction.

Authors:  Yun Deng; Rongquan He; Rui Zhang; Binliang Gan; Yu Zhang; Gang Chen; Xiaohua Hu
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

6.  Diallyl disulfide inhibits colon cancer metastasis by suppressing Rac1-mediated epithelial-mesenchymal transition.

Authors:  Longzheng Xia; Jingguan Lin; Jian Su; Linda Oyang; Heran Wang; Shiming Tan; Yanyan Tang; Xiaoyan Chen; Wenbin Liu; Xia Luo; Yutong Tian; Jiaxin Liang; Qi Su; Qianjin Liao; Yujuan Zhou
Journal:  Onco Targets Ther       Date:  2019-07-16       Impact factor: 4.147

7.  C1GALT1, Negatively Regulated by miR-181d-5p, Promotes Tumor Progression via Upregulating RAC1 in Lung Adenocarcinoma.

Authors:  Xiaoxia Dong; Yongyu Liu; Xinzhou Deng; Jun Shao; Shuangyue Tian; Shuang Chen; Rongxin Huang; Ziao Lin; Chunli Chen; Li Shen
Journal:  Front Cell Dev Biol       Date:  2021-07-07

8.  Identification of Key Genes and Pathways in Tongue Squamous Cell Carcinoma Using Bioinformatics Analysis.

Authors:  Huayong Zhang; Jianmin Liu; Xiaoyan Fu; Ankui Yang
Journal:  Med Sci Monit       Date:  2017-12-14

9.  Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis.

Authors:  Fanxin Zeng; Jiangping Fu; Fang Hu; Yani Tang; Xiangdong Fang; Fanwei Zeng; Yanpeng Chu
Journal:  Oncotarget       Date:  2018-03-05

10.  Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.

Authors:  Yangyang Cai; Xu Wang; Ye Guo; Chao Sun; Yinghui Xu; Shi Qiu; Kewei Ma
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.